Western Yilgarn Limited (ASX: WYX) has confirmed a significant surface discovery of high-grade gallium mineralisation at its Ida Holmes Junction Project in the Yilgarn Craton, Western Australia (Figure 1). With gallium identified by global authorities as a technology-critical element essential for semiconductors, LEDs, and solar panels, this development could place Western Yilgarn on the radar of strategic investors and downstream supply chain partners.

AML3D Limited (ASX: AL3), a pioneer in industrial-scale metal 3D printing, continues its global expansion with the announcement of a strategic UK distribution agreement. The company has appointed Arc Additive Limited, a Scotland-based specialist in wire arc additive manufacturing (WAAM), as its non-exclusive distribution partner across the UK and Europe.

Peak Minerals Limited (ASX: PUA) has confirmed a major expansion of heavy mineral (HM) mineralisation at its flagship Minta Rutile Project in Cameroon, with a 100% success rate from all 452 holes drilled (Figure 1). The program identified mineralisation across a vast 1,500km² zone—demonstrating scale and consistency in both residual and alluvial targets.

In the data security arena, momentum is everything, and archTIS Limited (ASX: AR9) is building a convincing narrative across multiple strategic fronts. From headline contract wins with the U.S. Department of Defense to entering the UK defence sector and securing fresh funding to fuel expansion, the Company has demonstrated alignment between strategic intent and market execution.

In its 29 July 2025 announcement, AuMEGA Metals Ltd (ASX: AAM | TSXV: AUM | OTCQB: AUMMF) delivered a substantial exploration update covering three major Canadian projects—Cape Ray, Bunker Hill, and Hermitage. With a fully funded program and a strong C$9.2 million treasury, AuMEGA is aggressively expanding its data-driven strategy across Newfoundland’s Cape Ray Shear Zone, Canada’s largest known gold-bearing structure.

Alterity Therapeutics Limited (ASX: ATH; NASDAQ: ATHE) has announced highly promising topline results from its open-label Phase 2 clinical trial (ATH434-202) evaluating ATH434 in patients with advanced Multiple System Atrophy (MSA). The findings reinforce the company’s position as a front-runner in developing disease-modifying therapies for neurodegenerative diseases.

Actinogen Medical Ltd (ASX: ACW) has announced a significant milestone in the development of its lead candidate, Xanamem®(emestedastat), with the 100th participant now enrolled in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial. This event formally triggers the timeline for an independent interim analysis of safety and efficacy, bringing the company one step closer to potentially introducing a novel oral therapy for Alzheimer’s disease (AD).

Great Boulder Resources Ltd (ASX:GBR) is moving confidently into the second half of 2025. In the span of just two weeks, the Company has expanded the mineralised footprint at Side Well, announced significant new gold intersections at Ironbark, and secured $12.5 million in funding to accelerate its exploration strategy.

Cyclone Metals Limited (ASX: CLE) has released its Quarterly Activities Report for the period ending 30 June 2025, and the momentum behind the Iron Bear Project is evident. Backed by a strategic partnership with Vale S.A., the quarter saw the completion of critical technical studies, advancement in metallurgical testing, progress across engineering and environmental baselines, and tangible steps toward the upcoming Scoping Study and PFS.

AML3D Limited (ASX: AL3) continues to solidify its reputation as a key enabler of defence manufacturing transformation. Over the June 2025 quarter, the company advanced its “US Scale Up” strategy with concrete progress in strategic partnerships, facility expansion, and order momentum. With a freshly announced order for a portable ARCEMY® system and a strong quarterly cash position of A$30.4 million, AML3D is not just building metal parts, but reshaping how defence manufacturi